Biotech Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business Update
Lpath creates new ocular division, names retinal specialist Glenn L. Stoller, MD, as head
May 18th, 2006
Lpath, Inc., a provider of therapeutic agents used against bioactive lipids, announced the creation of an ocular division to be headed by a retinal specialist. The new division will initially concentrate on a potential new drug for the treatment of age-related macular degeneration (AMD) and other eye diseases. On the strength of compelling preliminary results from an established animal model of AMD, the company believes its lead drug candidate Sphingomab has multiple applications in the treatment of eye diseases that lead to blindness. In addition to performing follow-on work in the AMD arena, Lpath will immediately begin...
Source: Biotech Business Week (2006-05-18)
|
